

![]() |
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
|
Authors | ![]() | |
Published in | Annals of the Rheumatic Diseases. 2013, vol. 72, no. 4, p. 482-92 | |
Abstract | Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion. | |
Keywords | Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects — Antirheumatic Agents/administration & dosage/adverse effects — Arthritis, Rheumatoid/drug therapy/immunology — Drug Monitoring/methods — Humans — Inflammation/drug therapy/immunology — Interleukin-6/antagonists & inhibitors — Receptors, Interleukin-6/antagonists & inhibitors | |
Identifiers | PMID: 23172750 | |
Full text | ||
Structures | ||
Research group | Mécanisme de l'inflammation articulaire (44) | |
Citation (ISO format) | SMOLEN, Josef S et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. In: Annals of the Rheumatic Diseases, 2013, vol. 72, n° 4, p. 482-92. doi: 10.1136/annrheumdis-2012-202469 https://archive-ouverte.unige.ch/unige:45809 |